GlaxoSmithKline PLC
LSE:GSK

Watchlist Manager
GlaxoSmithKline PLC Logo
GlaxoSmithKline PLC
LSE:GSK
Watchlist
Price: 1 339.5 GBX 0.41%
Market Cap: 54.7B GBX
Have any thoughts about
GlaxoSmithKline PLC?
Write Note

EV/EBITDA
Enterprise Value to EBITDA

6.2
Current
6.9
Median
13.5
Industry
Lower than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
6.2
=
Enterprise Value
65.2B GBX
/
EBITDA
10.6B GBP
All Countries
Close
Market Cap EV/EBITDA
UK
GlaxoSmithKline PLC
LSE:GSK
54.6B GBP 6.2
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY -5 459 134.4
US
Eli Lilly and Co
NYSE:LLY
755.8B USD 48.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 3 846.3
DK
Novo Nordisk A/S
CSE:NOVO B
2.7T DKK 20.2
US
Johnson & Johnson
NYSE:JNJ
351.1B USD 11.6
US
Merck & Co Inc
NYSE:MRK
251.8B USD 10.5
CH
Roche Holding AG
SIX:ROG
200.1B CHF 9.8
UK
AstraZeneca PLC
LSE:AZN
161.8B GBP 169.4
CH
Novartis AG
SIX:NOVN
171.5B CHF 9.4
US
Pfizer Inc
NYSE:PFE
151.5B USD 10.6
EBITDA Growth EV/EBITDA to Growth
UK
GlaxoSmithKline PLC
LSE:GSK
Average EV/EBITDA: 414.2
6.2
18%
0.3
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 459 134.4 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
48.5
195%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
151%
25.5
DK
Novo Nordisk A/S
CSE:NOVO B
20.2
84%
0.2
US
Johnson & Johnson
NYSE:JNJ
11.6
14%
0.8
US
Merck & Co Inc
NYSE:MRK
10.5
331%
0
CH
Roche Holding AG
SIX:ROG
9.8
23%
0.4
UK
AstraZeneca PLC
LSE:AZN
169.4
64%
2.7
CH
Novartis AG
SIX:NOVN
9.4
8%
1.2
US
Pfizer Inc
NYSE:PFE
10.6
31%
0.3

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
6.2
2-Years Forward
EV/EBITDA
5.7
3-Years Forward
EV/EBITDA
5.2

See Also

Discover More